Abstract
Free full text
Retraction: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
The journal and Chief Editors have retracted the 19 July 2021 article cited above.
Shortly after publication, our office received letters of complaint questioning the integrity of the article, following which an Expression of Concern was published and a thorough investigation was conducted, in accordance with our policies and COPE guidelines.
The investigation found that the claims made in the conclusions were not adequately supported by the methodology of the study. In particular, as confirmed by an external expert, the process of allocation to treatment and control was not sufficiently random.
This retraction was approved by the Chief Editors of Frontiers in Medicine and the Chief Executive Editor of Frontiers. The authors disagree with this retraction.
Articles from Frontiers in Medicine are provided here courtesy of Frontiers Media SA
Full text links
Read article at publisher's site: https://doi.org/10.3389/fmed.2022.964099
Read article for free, from open access legal sources, via Unpaywall: https://www.frontiersin.org/articles/10.3389/fmed.2022.964099/pdf
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Discover the attention surrounding your research
https://www.altmetric.com/details/129459754
Article citations
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.
Signal Transduct Target Ther, 9(1):223, 11 Sep 2024
Cited by: 0 articles | PMID: 39256346 | PMCID: PMC11412324
Review Free full text in Europe PMC
Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics.
Steroids, 210:109486, 05 Aug 2024
Cited by: 0 articles | PMID: 39111362
Review
Antiandrogens as Therapies for COVID-19: A Systematic Review.
Cancers (Basel), 16(2):298, 10 Jan 2024
Cited by: 1 article | PMID: 38254788 | PMCID: PMC10814161
Review Free full text in Europe PMC
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response.
Proc Natl Acad Sci U S A, 120(30):e2221809120, 17 Jul 2023
Cited by: 3 articles | PMID: 37459541 | PMCID: PMC10372636
The Problem with Capitalism in the Trichological Sciences.
Int J Trichology, 15(3):79-84, 01 May 2023
Cited by: 0 articles | PMID: 38179012 | PMCID: PMC10763731
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial.
Front Med (Lausanne), 8:668698, 19 Jul 2021
Cited by: 34 articles | PMID: 34350193 | PMCID: PMC8326462
Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial.
Front Med (Lausanne), 8:831449, 17 Jan 2022
Cited by: 1 article | PMID: 35111791 | PMCID: PMC8802327
Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine-A Study Protocol.
Front Med (Lausanne), 9:888928, 29 Mar 2022
Cited by: 0 articles | PMID: 35433723 | PMCID: PMC9005450
A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial [Retraction].
J Inflamm Res, 15:2381-2382, 14 Apr 2022
Cited by: 0 articles | PMID: 35444453 | PMCID: PMC9015672